
Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.
Participants receiving once-daily doses of oral VK2735 demonstrated a mean body weight reduction of up to 12.2% after 13 weeks from baseline.